Crinetics Pharmaceuticals, Inc.
CRNX
주식 순위
#2239
Crinetics Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical... Crinetics Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical enterprise, dedicated to the identification, advancement, and market introduction of therapeutic solutions for infrequent endocrine conditions and related tumors. Their flagship drug candidate, Paltusotine, is an orally administered, selective, non-peptide somatostatin receptor type 2 agonist. This compound has concluded its Phase III clinical trials for the treatment of acromegaly, and has also completed Phase II trials targeting carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). Furthermore, the company's pipeline includes CRN04777, an oral selective non-peptide somatostatin type 5 receptor agonist, which is currently undergoing Phase I clinical trials for congenital hyperinsulinism. Another investigational drug, CRN04894, an oral adrenocorticotrophic hormone antagonist, is in Phase I clinical trials for Cushing's disease and congenital adrenal hyperplasia. Crinetics Pharmaceuticals, Inc. was founded in 2008 and maintains its headquarters in San Diego, California.
주가
$84.95
마지막 동기화: 2026-09-01
시가총액
$9.00B
변동 (1일)
0.00%
변동 (1년)
98.25%
국가
US
거래 Crinetics Pharmaceuticals, Inc. (CRNX)
카테고리
Healthcare
Crinetics Pharmaceuticals, Inc. (CRNX)의 발행 주식 수
June 2026 기준 발행 주식 수: 105.56M
Crinetics Pharmaceuticals, Inc.의 최신 재무 보고서와 주가에 따르면 현재 발행 주식 수는 105.56M입니다. December 2023 말 기준 회사는 58.07M주를 발행했습니다. 발행 주식 수는 일반적으로 주식 분할이나 자사주 매입에 의해 영향을 받습니다.
Crinetics Pharmaceuticals, Inc. (CRNX)의 발행 주식 수 기록 (2016 ~ 2026)
매년 말 기준 발행 주식 수
| 연도 | 발행 주식 수 | 변화 |
|---|---|---|
| 2026 (TTM) | 105.56M | 30.67% |
| 2024 | 80.78M | 39.11% |
| 2023 | 58.07M | 11.71% |
| 2022 | 51.98M | 35.24% |
| 2021 | 38.44M | 26.23% |
| 2020 | 30.45M | 25.95% |
| 2019 | 24.18M | 99.10% |
| 2018 | 12.14M | -12.51% |
| 2017 | 13.88M | 0.00% |
| 2016 | 13.88M | 0.00% |
유사 기업 또는 경쟁사의 발행 주식 수
| 회사 | 발행 주식 수 | 차이 | 국가 |
|---|---|---|---|
| 253.90M | 140.53% |
US
|
|
| 396.00M | 275.14% |
US
|
|
| 478.91M | 353.69% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -41.09% |
NL
|
